secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001493152-24-007147
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics to present MS data at ACTRIMS; phase 0/1 shows safety, no adverse events
--------------------------------------------------------------------------------

- Phase 0/1 safety trial of allogeneic HDFs in 5 MS patients: no adverse events, strong CBC/blood chemistry/ECG correlation.
- In vivo EAE model: HDFs suppressed Th17, expanded Tregs, stimulated remyelination, outperformed adipose/bone marrow MSCs.
- Company designing phase II trial to test various HDF spheroid doses and multiple-dose treatments over 18 months.
- Presentation at ACTRIMS Forum 2024 on Feb 29 in West Palm Beach, FL (poster P341).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224007147/0001493152-24-007147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224007147/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer